- After-Shows
- Alternative
- Animals
- Animation
- Arts
- Astronomy
- Automotive
- Aviation
- Baseball
- Basketball
- Beauty
- Books
- Buddhism
- Business
- Careers
- Chemistry
- Christianity
- Climate
- Comedy
- Commentary
- Courses
- Crafts
- Cricket
- Cryptocurrency
- Culture
- Daily
- Design
- Documentary
- Drama
- Earth
- Education
- Entertainment
- Entrepreneurship
- Family
- Fantasy
- Fashion
- Fiction
- Film
- Fitness
- Food
- Football
- Games
- Garden
- Golf
- Government
- Health
- Hinduism
- History
- Hobbies
- Hockey
- Home
- How-To
- Improv
- Interviews
- Investing
- Islam
- Journals
- Judaism
- Kids
- Language
- Learning
- Leisure
- Life
- Management
- Manga
- Marketing
- Mathematics
- Medicine
- Mental
- Music
- Natural
- Nature
- News
- Non-Profit
- Nutrition
- Parenting
- Performing
- Personal
- Pets
- Philosophy
- Physics
- Places
- Politics
- Relationships
- Religion
- Reviews
- Role-Playing
- Rugby
- Running
- Science
- Self-Improvement
- Sexuality
- Soccer
- Social
- Society
- Spirituality
- Sports
- Stand-Up
- Stories
- Swimming
- TV
- Tabletop
- Technology
- Tennis
- Travel
- True Crime
- Episode-Games
- Visual
- Volleyball
- Weather
- Wilderness
- Wrestling
- Other
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting. In this podcast, Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, Harry Erba, MD, PhD, Duke University, Durham, NC, and Jessica Altman, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, discuss new treatments in AML, drawing focus on FLT3 inhibitors, novel combinations, and treating patients with relapsed disease. The post iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more appeared first on VJHemOnc.